Pediatric Drugs

Papers
(The H4-Index of Pediatric Drugs is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Cardioprotective Effect of Nigella sativa in Pediatric Patients with Type 1 Diabetes Mellitus: A Randomized Controlled Study75
Common Selfcare Indications of Pain Medications in Children58
Impact of Antiseizure Medications on Appetite and Weight in Children50
Alirocumab: Pediatric First Approval40
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury34
Pitolisant: Pediatric First Approval34
Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs33
Diagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update28
Correction: Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial28
Comment on: “The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial”27
Authors’ Reply to Sethuraman’s comment on “The Effect of Alfentanil on Emergence Delirium Following General Anesthesia in Children: A Randomized Clinical Trial”26
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis25
Diagnosis of Serious Conditions Delayed in Association with Ondansetron Treatment for Vomiting in the Pediatric Emergency Department25
Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives24
Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature22
Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations22
Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)21
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1–6 Months of Age21
Drug–Drug Interactions Involving High-Alert Medications that Lead to Interaction-Associated Symptoms in Pediatric Intensive Care Patients: A Retrospective Study20
Pediatric Drugs, Accelerated Approval, and Prospects for Reform20
0.056200981140137